Crewther Sheila G, Murphy Melanie J, Crewther David P
School of Psychological Science, La Trobe University, Melbourne, Australia.
PLoS One. 2008 Jul 30;3(7):e2839. doi: 10.1371/journal.pone.0002839.
Myopia affects well over 30% of adult humans globally. However, the underlying physiological mechanism is little understood. This study tested the hypothesis that ocular growth and refractive compensation to optical defocus can be controlled by manipulation of potassium and chloride ion-driven transretinal fluid movements to the choroid. Chicks were raised with +/-10D or zero power optical defocus rendering the focal plane of the eye in front of, behind, or at the level of the retinal photoreceptors respectively. Intravitreal injections of barium chloride, a non-specific inhibitor of potassium channels in the retina and RPE or bumetanide, a selective inhibitor of the sodium-potassium-chloride cotransporter were made, targeting fluid control mechanisms. Comparison of refractive compensation to 5 mM Ba(2+) and 10(-5) M bumetanide compared with control saline injected eyes shows significant change for both positive and negative lens defocus for Ba(2+) but significant change only for negative lens defocus with bumetanide (Rx(SAL)(-10D) = -8.6 +/- .9 D; Rx(Ba2+)(-10D) = -2.9 +/- .9 D; Rx(Bum)(-10D) = -2.9 +/- .9 D; Rx(SAL)(+10D) = +8.2 +/- .9 D; Rx(Ba2+)(+10D) = +2.8 +/- 1.3 D; Rx(Bum)(+10D) = +8.0 +/- .7 D). Vitreous chamber depths showed a main effect for drug conditions with less depth change in response to defocus shown for Ba(2+) relative to Saline, while bumetanide injected eyes showed a trend to increased depth without a significant interaction with applied defocus. The results indicate that both K channels and the NKCC cotransporter play a role in refractive compensation with NKCC blockade showing far more specificity for negative, compared with positive, lens defocus. Probable sites of action relevant to refractive control include the apical retinal pigment epithelium membrane and the photoreceptor/ON bipolar synapse. The similarities between the biometric effects of NKCC inhibition and biometric reports of the blockade of the retinal ON response, suggest a possible common mechanism. The selective inhibition of refractive compensation to negative lens in chick by loop diuretics such as bumetanide suggests that these drugs may be effective in the therapeutic management of human myopia.
全球超过30%的成年人受近视影响。然而,其潜在的生理机制却鲜为人知。本研究检验了一种假说,即通过操纵钾离子和氯离子驱动的经视网膜至脉络膜的液体流动,可以控制眼球生长以及对光学离焦的屈光补偿。将雏鸡饲养在分别具有±10D或零屈光度光学离焦的环境中,使眼睛的焦平面分别位于视网膜光感受器前方、后方或与之平齐。向玻璃体内注射氯化钡(一种视网膜和视网膜色素上皮中钾通道的非特异性抑制剂)或布美他尼(一种钠-钾-氯共转运体的选择性抑制剂),以针对液体控制机制。将注射5 mM Ba(2+)和10(-5) M布美他尼后的屈光补偿与注射对照生理盐水的眼睛进行比较,结果显示,对于Ba(2+),正负透镜离焦均有显著变化,但布美他尼仅对负透镜离焦有显著变化(Rx(SAL)(-10D) = -8.6 ± 0.9 D;Rx(Ba2+)(-10D) = -2.9 ± 0.9 D;Rx(Bum)(-10D) = -2.9 ± 0.9 D;Rx(SAL)(+10D) = +8.2 ± 0.9 D;Rx(Ba2+)(+10D) = +2.8 ± 1.3 D;Rx(Bum)(+10D) = +8.0 ± 0.7 D)。玻璃体腔深度显示出药物条件的主要影响,相对于生理盐水,Ba(2+)对离焦的反应中深度变化较小,而注射布美他尼的眼睛显示出深度增加的趋势,但与施加的离焦无显著相互作用。结果表明,钾通道和钠-钾-氯共转运体在屈光补偿中均起作用,与正透镜离焦相比,钠-钾-氯共转运体阻断对负透镜离焦表现出更高的特异性。与屈光控制相关的可能作用位点包括视网膜色素上皮顶端膜和光感受器/双极细胞突触。钠-钾-氯共转运体抑制的生物测量效应与视网膜ON反应阻断的生物测量报告之间的相似性,提示可能存在共同机制。布美他尼等袢利尿剂对雏鸡负透镜屈光补偿的选择性抑制表明,这些药物可能对人类近视的治疗有效。